Udho Thadani to Double-Blind Method
This is a "connection" page, showing publications Udho Thadani has written about Double-Blind Method.
Connection Strength
0.603
-
The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 04; 40(11):2006-12.
Score: 0.049
-
Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2021 05 01; 146:36-47.
Score: 0.043
-
Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris. Am J Cardiol. 1997 Apr 15; 79(8):1025-30.
Score: 0.033
-
Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group. Circulation. 1994 Aug; 90(2):726-34.
Score: 0.027
-
Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST) Circulation. 1994 Aug; 90(2):762-8.
Score: 0.027
-
Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Diltiazem CD Study Group. Am J Cardiol. 1994 Jul 01; 74(1):9-17.
Score: 0.027
-
Duration of effects of isradipine during twice daily therapy in angina pectoris. Cardiovasc Drugs Ther. 1994 Apr; 8(2):199-210.
Score: 0.027
-
Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Intern Med. 1994 Mar 01; 120(5):353-9.
Score: 0.026
-
Effects of 8:00 a.m. and 2:00 p.m. doses of isosorbide-5-mononitrate during twice-daily therapy in stable angina pectoris. Am J Cardiol. 1992 Aug 01; 70(3):286-92.
Score: 0.024
-
Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. Circulation. 1991 Dec; 84(6):2398-408.
Score: 0.023
-
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 2011 Oct 25; 124(17):1811-8.
Score: 0.022
-
A multicenter comparison of isradipine and prazosin for treatment of essential hypertension. Cardiovasc Drugs Ther. 1990 Apr; 4(2):413-7.
Score: 0.020
-
Long-term bepridil monotherapy for angina pectoris. Am J Cardiol. 1988 Jun 01; 61(15):1210-3.
Score: 0.018
-
Usefulness of twice-daily isosorbide-5-mononitrate in preventing development of tolerance in angina pectoris. Am J Cardiol. 1987 Sep 01; 60(7):477-82.
Score: 0.017
-
Isosorbide-5-mononitrate in angina pectoris: plasma concentrations and duration of effects after acute therapy. Clin Pharmacol Ther. 1987 Jul; 42(1):58-65.
Score: 0.017
-
Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris. Am J Cardiol. 1987 Apr 01; 59(8):756-62.
Score: 0.016
-
The effectiveness of transcutaneous nitrate preparations for angina pectoris. Int J Cardiol. 1987 Jan; 14(1):9-14.
Score: 0.016
-
Transdermal nitroglycerin patches in angina pectoris. Dose titration, duration of effect, and rapid tolerance. Ann Intern Med. 1986 Oct; 105(4):485-92.
Score: 0.016
-
Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005 Nov 15; 46(10):1803-11.
Score: 0.015
-
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005 Jun 27; 165(12):1401-9.
Score: 0.014
-
Comparative efficacy of 200, 300 and 400 mg of bepridil for chronic stable angina pectoris. Am J Cardiol. 1985 Mar 15; 55(7):36C-42C.
Score: 0.014
-
Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol. 2003 Dec 17; 42(12):2049-59.
Score: 0.013
-
Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J. 2003 Dec; 24(24):2206-12.
Score: 0.013
-
Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. Am J Cardiol. 2003 Feb 01; 91(3):274-9.
Score: 0.012
-
Usefulness of clinical information to distinguish patients with normal from those with low ejection fractions in heart failure. Am J Cardiol. 2002 May 15; 89(10):1218-21.
Score: 0.012
-
Propranolol in angina pectoris: comparison of therapy given two and four times daily. Am J Cardiol. 1980 Jul; 46(1):117-23.
Score: 0.010
-
Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris. Am J Med. 1980 Feb; 68(2):243-50.
Score: 0.010
-
Effects of glucose-insulin-potassium infusion on the angina response during treadmill exercise. Cardiology. 1979; 64(6):333-49.
Score: 0.009
-
Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation. 1998 Nov 17; 98(20):2117-25.
Score: 0.009
-
Effect of morning versus evening dosing of diltiazem on myocardial ischemia detected by ambulatory electrocardiographic monitoring in chronic stable angina pectoris. Dilacor XR Ambulatory Ischemia Study Group. Am J Cardiol. 1997 Aug 15; 80(4):421-5.
Score: 0.008
-
Effects of zatebradine (ULFS 49 CL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina pectoris. Zatebradine Investigators. Am J Cardiol. 1997 May 15; 79(10):1401-5.
Score: 0.008
-
Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. Am Heart J. 1995 Mar; 129(3):527-35.
Score: 0.007